Literature DB >> 34662231

Fourth Boy Dies in Clinical Trial of Astellas' AT132.

Alex Philippidis1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34662231     DOI： 10.1089/hum.2021.29182.bfs

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  6 in total

1.  Evolution of drug delivery systems: From 1950 to 2020 and beyond.

Authors:  Haesun Park; Andrew Otte; Kinam Park
Journal:  J Control Release       Date:  2021-12-29       Impact factor: 11.467

Review 2.  Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot.

Authors:  Harry Wilton-Clark; Toshifumi Yokota
Journal:  Genes (Basel)       Date:  2022-01-28       Impact factor: 4.096

Review 3.  Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Jacques P Tremblay
Journal:  Front Med (Lausanne)       Date:  2022-03-28

Review 4.  Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.

Authors:  Bénédicte Delire; Eleonora De Martin; Lucy Meunier; Dominique Larrey; Yves Horsmans
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

5.  Clinical gene technology in Australia: building on solid foundations.

Authors:  Gabrielle O'Sullivan; Joshua G Philips; John Ej Rasko
Journal:  Med J Aust       Date:  2022-07-18       Impact factor: 12.776

Review 6.  Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders.

Authors:  Tomoki Hirunagi; Kentaro Sahashi; Katherine G Meilleur; Masahisa Katsuno
Journal:  Genes (Basel)       Date:  2022-01-05       Impact factor: 4.096
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.